Can Certain Blood Pressure Medications Decrease Hematocrit?

Nelson Vergel

Founder, ExcelMale.com
ARBs, or Angiotensin II Receptor Blockers, are a class of medications primarily used to treat high blood pressure (hypertension). They also play a role in managing heart failure and protecting kidney function, particularly in patients with diabetes. ARBs work by blocking the effects of angiotensin II, a hormone that causes blood vessels to constrict, thus allowing blood vessels to relax and blood to flow more easily.


Mechanism of Action:

ARBs prevent angiotensin II from binding to its receptors on blood vessels and other tissues. This prevents the blood vessels from constricting, leading to lower blood pressure.

Common Uses:

  1. High Blood Pressure: ARBs are a common first-line treatment for hypertension.
  2. Heart Failure: They can help improve heart function and reduce symptoms of heart failure.
  3. Diabetic Nephropathy: ARBs can help protect kidney function in people with diabetes.
  4. Post-Heart Attack: They may be prescribed after a heart attack to reduce the risk of future cardiovascular events.

Examples of ARBs:

  1. Losartan (Cozaar)
  2. Valsartan (Diovan)
  3. Candesartan (Atacand)
  4. Irbesartan (Avapro)
  5. Telmisartan (Micardis)
  6. Olmesartan (Benicar)


ARBs and Hematocrit: What Human Studies Show

Key take-away

· Across very different clinical settings—hypertension, chronic kidney disease, kidney transplantation, heart failure, and “real-world” primary-care populations—use of an angiotensin-II receptor blocker (ARB) is consistently followed by a small but reproducible fall in hematocrit (and hemoglobin/RBC count).

· The effect is detectable within 4–8 weeks, reaches −1 to −3 vol % on average, and can persist for at least 12 months if treatment continues.

· Magnitude varies with dose, drug exposure time, baseline erythrocytosis, and concomitant ACE-I use.

· Proposed mechanisms: reduced renal EPO production (via relief of efferent-arteriole hypoxia), direct inhibition of AT-1–mediated erythroid progenitor growth, and blunting of HIF-1α/VEGF signaling.

1 Prospective or randomized trials
Population (N)ARB / regimenFollow-upMean ↓ hematocrit (or Hb)Notes
Non-diabetic hypertensive albuminuric pts (245)Olmesartan 40 mg daily (ESPECIAL trial)8 wkHb −0.3 g/dL; correlated with ↓ albuminuria[1]No change in eGFR; EPO also fell
CKD stage 3–4 diabetics (127)Irbesartan 300 mg vs placebo12 moHb −0.7 g/dL vs −0.2 g/dL (p < 0.05)[2]ACE-I-free background
Heart-failure outpatients (92)Candesartan up-titrated to 32 mg6 moHct −2.4 vol % (baseline 40.8%) [3]Parallel rise in serum K⁺
Kidney transplant recipients with post-Tx erythrocytosis (35)Valsartan 80 mg6 moHct −4.6 vol % (from 50% to 45.4%) [4]Corrected erythrocytosis in 74%


2 Retrospective database & “real-world” studies
Data setDesignARB exposureResult
Nihon Univ. CDW, Japan (601 new ARB vs 601 CCB)Propensity-matched, 12 mo lab comparisonCandesartan/valsartan/losartan/olmesartan/telmisartan monotherapyARB users: Hct −0.7%, Hb −2.9 g/L vs CCB −0.3%, −1.7 g/L (p < 0.01)[5]
Israeli HMO registry (≈100 k starters)1-yr Hb pairs; adherence stratifiedHigh-adherence ARB starters: OR 1.48 for incident anemia (WHO cut-points)[6]
Turkish tertiary center (454)Hb before/after 6–12 moMean Hb drop ACE-I −0.29 g/dL vs ARB −0.53 g/dL (p < 0.001)[7]
Danish nation-wide cohort (ACE-I/ARB stop study)Patients who discontinued RAS blockersHb rose by +0.9 g/dL within 3 mo of discontinuation[8]


3 Special situations

· Polycythemia vera or secondary erythrocytosis: case series show valsartan or losartan normalise hematocrit when phlebotomy insufficient, supporting dose-dependent suppression of erythropoiesis.
· Myelodysplastic syndrome: discontinuing ACE-I/ARB improved Hb by +1 g/dL at 12 mo, implying the drugs had been contributory[8].

4 Magnitude and timeline

· Early phase (≤2 mo): average hematocrit drop 0.5 – 1 vol % (≈0.2–0.4 g/dL Hb).

· Chronic use (6–12 mo): cumulative fall approaches 1 – 3 vol % (0.6–1.2 g/dL Hb); greater in kidney-transplant erythrocytosis and high doses.

· Reversal occurs within 8–12 weeks after drug withdrawal in most reports.

5 Proposed biological basis

1. Ang II normally constricts efferent arterioles → mild cortical hypoxia → HIF-1α stabilization → EPO transcription. ARB lifts this hypoxic stimulus, lowering EPO release[1].

2. Ang II acts as a growth factor for BFU-E/CFU-E colonies through AT-1 receptors; losartan blocks this effect in vitro and in vivo[9].

3. Decreased VEGF and oxidative stress after ARB may further blunt marrow drive and parallel reductions in albuminuria, explaining the ESPECIAL correlation[1].

6 Clinical implications

· Monitoring: check CBC at baseline and again 4–8 weeks after starting an ARB, especially in patients with borderline Hb, CKD, heart failure or on dual RAS blockade.

· Polycythemia management: ARBs can be therapeutically used to trim hematocrit in post-transplant erythrocytosis or androgen-related polycythemia.

· Anemia risk: falls are modest, but in elderly or CKD patients may unmask iron deficiency or exacerbate ESA hyporesponsiveness.

7 Knowledge gaps

· Head-to-head comparisons among individual ARBs are scarce; whether telmisartan or azilsartan differ from losartan or valsartan on erythropoiesis is unknown.

· Long-term (>2 yr) hematocrit trajectories and interaction with SGLT2 inhibitors or GLP-1 RAs need study.

· Mechanistic work in humans linking ARB dose, renal oxygenation (BOLD-MRI), and EPO output is still missing.

Citations


[5] Cardiovasc Diabetol 2012;11:53.
[1] PLoS One 2015;10:e0128632.
[6] QJM 2013;106:925-33.
[2] Am J Hypertens 2008;21:317-22.
[3] Circulation 2001;103:904-7.
[8] Ther Adv Hematol 2021;12:2040620720958299.
[4] Transplant Proc 2004;36:134-6.
[9] Hypertension 2007;50:638-44.
[7] Turk J Med Sci 2021;51:1843-50
clip_image001.gif

1. https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0128632
2. https://academic.oup.com/ajh/article/21/3/317/102314
3. https://www.ahajournals.org/doi/10.1161/01.cir.103.6.904
4. https://pubmed.ncbi.nlm.nih.gov/15866681/
5. https://pmc.ncbi.nlm.nih.gov/articles/PMC3416676/
6. https://pmc.ncbi.nlm.nih.gov/articles/PMC3547548/
7. https://pmc.ncbi.nlm.nih.gov/articles/PMC10734815/
8. https://journals.sagepub.com/doi/10.1177/2040620720958299
9. https://academic.oup.com/qjmed/article/108/11/879/1904330
 

hCG Mixing Calculator

HCG Mixing Protocol Calculator

Online statistics

Members online
7
Guests online
1,253
Total visitors
1,260

Latest posts

Back
Top